AI Article Synopsis
- Researchers assessed 147 liver transplant patients to determine how common hyperkalemia (elevated potassium levels) is after surgery and what factors contribute to it.
- They found that 18.4% of patients experienced hyperkalemia one month post-transplant, with the prevalence dropping to 6.1% by the twelfth month.
- Factors like older age, low kidney function, high urea levels, and certain medication dosages were linked to a higher risk of hyperkalemia, suggesting that treatment should be personalized based on individual risk factors.
Article Abstract
Background: There is a lack of data regarding hyperkalemia after liver transplantation.
Aim: To evaluate the prevalence of hyperkalemia after liver transplantation and its associated factors.
Methods: This retrospective cohort study evaluated 147 consecutive post-transplant patients who had at least one year of outpatient medical follow up. The data collection included gender, age, potassium values, urea, creatinine, sodium and medication use at 1, 6 and 12 months after. Hyperkalemia was defined as serum potassium concentrations higher than 5.5 mEq/l.
Results: Hiperkalemia was observed in 18.4%, 17.0% and 6.1% of patients 1, 6 and 12 months after tranplantation, respectively. Older age (p=0.021), low creatinine clearance (p=0.007), increased urea (p=0.010) and hypernatremia (p=0.014) were factors associated with hyperkalemia, as well as the dose of prednisone at six months (p=0.014).
Conclusion: Hyperkalemia was prevalent in less than 20% of patients in the 1st month after liver transplantation and decreased over time. Considering that hyperkalemia does not affect all patients, attention should be paid to the routine potassium intake recommendations, and treatment should be individualized.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6050000 | PMC |
| http://dx.doi.org/10.1590/0102-672020180001e1357 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Successful treatment of tumor lysis syndrome associated with hepatic artery infusion chemotherapy in a patient with hepatocellular carcinoma: a case report.
J Med Case Rep
December 2024
Liver Cancer Institute, National Clinical Research Center for Interventional Medicine, Zhongshan Hospital, Fudan University, 136 Yi Xue Yuan Road, Shanghai, 200032, People's Republic of China.
Background: Tumor lysis syndrome is a life-threatening complication in the treatment of cancer. However, it rarely occurs in solid tumors, especially in hepatocellular carcinoma.
Case Presentation: We present a 52-year-old male Asian patient with advanced hepatocellular carcinoma treated with hepatic artery infusion chemotherapy that resulted in tumor lysis syndrome.
Severe Exertional Rhabdomyolysis in a Healthy 24-Year-Old Woman: A Case Report and Review of Literature.
Cureus
November 2024
Internal Medicine, Howard University Hospital, Washington, DC, USA.
Rhabdomyolysis is characterized by the release of muscle cell components into circulation following muscle cell injury. Common causes include trauma and compression, exposure to drugs and toxins, and intense physical exercise. This study depicts a case of exercise-induced rhabdomyolysis following a cycling class.
View Article and Find Full Text PDFSafety and tolerability of losartan to treat recessive dystrophic epidermolysis bullosa in children (REFLECT): an open-label, single-arm, phase 1/2 trial.
EClinicalMedicine
November 2024
Department of Dermatology, Medical Center- University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Article Synopsis
- Recessive dystrophic epidermolysis bullosa (RDEB) is a severe skin condition that causes blisters and other complications, and this study tested the safety of losartan, a medication that may slow its progression.
- The study was a phase 1/2 trial involving children aged 2-16 with confirmed RDEB, focusing on identifying any serious side effects of losartan over a treatment period of 10 months.
- Primary safety concerns monitored included severe drops in blood pressure, allergic reactions, and changes in potassium levels, along with evaluating the drug's effectiveness through various clinical scores.
Efficacy and safety of calcineurin inhibitors (CNIs) for septic patients in ICU: a cohort study from MIMIC database.
Front Pharmacol
September 2024
Department of Critical Care Medicine, Zhejiang Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Article Synopsis
- Sepsis involves an uncontrolled immune response to infections, and the study investigates whether calcineurin inhibitors (CNIs), typically used to suppress the immune system, can improve outcomes for septic patients.
- Utilizing data from the MIMIC-IV database, the researchers compared septic patients treated with CNIs to those who were not, with a focus on 28-day mortality rates and potential side effects.
- The findings show that CNI users had significantly lower mortality rates and better survival over both 28 and 365 days, but they might experience mild hypertension and liver injury without an increase in new infections.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!